PPARα agonists have been shown to decrease the growth of melanoma, glioblastoma, and fibrosarcoma, and these effects have been associated with PPARα-induced inhibition of endothelial cell proliferation as well as PPARα-dependent down-regulation of cytochrome P450, resulting in inhibition of neoangiogenesis [29], [30]. Here, PPARA is linked to melanoma.